Amylx Pharmaceuticals Inc vs Direxion Daily Semiconductor Bull 3X Shares — how do they compare? Amylx Pharmaceuticals Inc trades at $23.49 (market cap $2.64B), while Direxion Daily Semiconductor Bull 3X Shares trades at $142.84. The key difference: Amylx Pharmaceuticals Inc is trading nearer its 52-week high, Direxion Daily Semiconductor Bull 3X Shares nearer its low. Which is the better fit depends on your goals.
| AMLX | SOXL | |
|---|---|---|
Market Cap | $2.64B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $24.19 | $300.77 |
52-Week Low | $7.82 | $24.91 |
Enterprise Value | $2.39B | — |
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $23.61, up 4.15% today, with strong analyst support (91% buy ratings) and a $30 consensus price target. The stock shows bullish technical momentum despite negative profitability metrics (ROE -74.73%, ROA -66.25%). Recent Q2 2026 earnings missed expectations, but the company maintains $250.8M cash runway into 2028, supporting its pivotal Phase 3 LUCIDITY trial readout expected August-September 2026.
The investment thesis hinges on successful avexitide clinical outcomes, with potential 2027 launch offering significant upside. Key risks include ongoing financial losses, clinical trial execution, and competitive pressures. Current valuation at 11.02x book value appears stretched given negative earnings, making positive trial results critical for justifying premium pricing.
SOXL, the Direxion Daily Semiconductor Bull 3X Shares ETF, surged 13.02% to $146.92 amid renewed semiconductor sector optimism. The leveraged ETF remains in a technical bearish trend despite the recent rally, with moving averages signaling continued downward pressure. Recent news highlights significant government semiconductor funding and AI-driven demand catalysts, though the fund has experienced extreme volatility, dropping over 60% from its peak earlier this year before this rebound.
The outlook remains volatile with leveraged exposure amplifying both gains and losses. Investment opportunity exists for aggressive investors betting on sustained semiconductor recovery and AI infrastructure spending, but risks include extreme volatility decay, sector concentration, and macroeconomic sensitivity. The current technical setup suggests cautious entry near support levels may offer better risk-reward positioning.
Trailing returns across standard periods
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →SOXL is a leveraged ETF that seeks daily investment results corresponding to 300% of the daily performance of the ICE Semiconductor Index. It is designed as a tactical tool for experienced traders to take a bullish (long) position on the semiconductor sector. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment.
Read more on SOXL →